Last reviewed · How we verify
Investigational Cancer Drug — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Investigational Cancer Drug (Investigational Cancer Drug) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Investigational Cancer Drug TARGET | Investigational Cancer Drug | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Investigational Cancer Drug CI watch — RSS
- Investigational Cancer Drug CI watch — Atom
- Investigational Cancer Drug CI watch — JSON
- Investigational Cancer Drug alone — RSS
Cite this brief
Drug Landscape (2026). Investigational Cancer Drug — Competitive Intelligence Brief. https://druglandscape.com/ci/investigational-cancer-drug. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab